UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

AIDS (London), 2021-07, Vol.35 (9), p.1333-1342

2021

Volltextzugriff (PDF)

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects

British journal of clinical pharmacology, 2022-10, Vol.88 (10), p.4607-4622

2022

Volltextzugriff (PDF)

Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects

Journal of acquired immune deficiency syndromes (1999), 2009-05, Vol.51 (1), p.20

2009

Volltextzugriff (PDF)

Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir

The Annals of pharmacotherapy, 2004-12, Vol.38 (12), p.2171

2004

Volltextzugriff (PDF)

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

The New England journal of medicine, 2020-03, Vol.382 (12), p.1124-1135

2020

Volltextzugriff (PDF)

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Journal of acquired immune deficiency syndromes (1999), 2020-12, Vol.85 (4), p.498

2020

Volltextzugriff (PDF)

Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy

HIV medicine, 2023-02, Vol.24 (2), p.202-211

2023

Volltextzugriff (PDF)

Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project

Clinical pharmacology and therapeutics, 2023-07, Vol.114 (1), p.29-40

2023

Volltextzugriff (PDF)

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

Clinical therapeutics, 2001-10, Vol.23 (10), p.1603-1614

2001

Volltextzugriff (PDF)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses

PloS one, 2019-11, Vol.14 (11), p.e0225199

2019

Volltextzugriff (PDF)

Abacavir and the potential risk of myocardial infarction

The Lancet (British edition), 2008-04, Vol.371 (9622), p.1413-1413

2008

Volltextzugriff (PDF)

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

JAMA : the journal of the American Medical Association, 2001-03, Vol.285 (9), p.1155

2001

Volltextzugriff (PDF)

A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects

Liver international, 2014-07, Vol.34 (6), p.e89-e95

2014

Volltextzugriff (PDF)

A Double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK 2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects

Liver international, 2014-07, Vol.34 (6)

2014

Volltextzugriff (PDF)

884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S20-S20

2019

Volltextzugriff (PDF)

Risk factor analysis of hypersensitivity reactions to abacavir

Clinical therapeutics, 2002-04, Vol.24 (4), p.565-573

2002

Volltextzugriff (PDF)

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy

AIDS (London), 2000-01, Vol.14 (2), p.163-171

2000

Volltextzugriff (PDF)

Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor : age inversely predicts naive CD4 cell count increase

AIDS (London), 2000-12, Vol.14 (17), p.2635-2642

2000

Volltextzugriff (PDF)

The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients : results from a randomized, double-blind, trial

AIDS (London), 2000-05, Vol.14 (7), p.781-789

2000

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(29)

Publikationsform

Sprache

Englisch
(34)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(22)
Humans
(21)
Hiv Infections - Drug Therapy
(16)
Adult
(14)
Anti-Hiv Agents - Adverse Effects
(12)
Female
(12)
Hiv
(12)
Infectious Diseases
(12)
Male
(11)
Biological And Medical Sciences
(10)
Drug Therapy, Combination
(10)
Medical Sciences
(10)
Anti-Hiv Agents - Administration & Dosage
(9)
Human Immunodeficiency Virus
(9)
Middle Aged
(9)
Pharmacology. Drug Treatments
(9)
Abacavir
(8)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(8)
Antiretroviral Therapy
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure

Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min

Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses

Abacavir and the potential risk of myocardial infarction

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects

A Double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK 2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects

884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies

Predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis across three phase 3 studies

Risk factor analysis of hypersensitivity reactions to abacavir

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy

Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor : age inversely predicts naive CD4 cell count increase

The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients : results from a randomized, double-blind, trial

Suchergebnisse filtern